conclusions adiponectin exerts a NO-dependent vasodilation in resistance arteries of normoglycemic ZL rats, but not diabetic ZDF rats. This may contribute to endothelial dysfunction in ZDF rats. alterations in the expression of aPPL1 may be involved in the observed insensitivity to adiponectin in ZDF rats.
Adiponectin is specifically and abundantly expressed in adipose tissue. 1, 2 It is a 30-kDa protein consisting of a N-terminal collagenous domain and a C-terminal globular domain. In the circulation adiponectin exists as a full-length form (fAd) and a putative proteolytic cleavage product consisting of the globular domain (gAd). 3, 4 It exerts insulin-sensitizing and antiinflammatory actions as reviewed elsewhere. 5, 6 These effects are mediated via binding to two specific transmembrane receptors, adiponectin receptor 1 (AdipoR1) and adiponectin receptor 2 (AdipoR2), 7, 8 respectively. Unexpectedly, decreased plasma levels of adiponectin were observed in obesity and its comorbidities like insulin resistance and the metabolic syndrome. 2, 9, 10 Because, likewise in some human studies the adiponectin receptors were found to be downregulated in muscle cells in these states, 11, 12 a reduced sensitivity to adiponectin and hypoadiponectinemia itself, which is recognized as a marker of adipose tissue dysfunction, 13 may serve as a link between obesity and its related diseases. 14, 15 However, it has to be mentioned that in studies with Zucker diabetic fatty (ZDF) rats the adiponectin receptors in comparison to lean rats were not downregulated in muscle cells, but decreased in white adipose tissue and increased in the liver. 16, 17 Otherwise recently in a mice model of diabetes mellitus the first described adaptor protein for both adiponectin receptors, adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 1 (APPL1), was found to be downregulated. 18 Further its protein isoform, adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 2 (APPL2), Background adiponectin increases nitric oxide (NO) production in endothelial cell cultures and is reduced in the circulation of obese and diabetic patients, but its functional effect on resistance arteries is not yet studied in detail.
Methods
We assessed the direct vasodilatory response of isolated mesenteric resistance arteries of Zucker diabetic fatty (ZDF) rats and Zucker lean (ZL) rats to globular adiponectin (gad) and full-length adiponectin (fad) and tested the effect of additional reactive oxygen species (rOS) inhibitors in vitro. Serum adiponectin and insulin levels were measured by ELISa. The mrNa expressions of the adiponectin receptors and the downstream signaling molecules adaptor protein, phosphotyrosine interaction, Ph domain and leucine zipper containing 1 (aPPL1), adaptor protein, phosphotyrosine interaction, Ph domain and leucine zipper containing 2 (aPPL2), and endothelial NO synthase (eNOS) in mesenteric resistance arteries were quantified by real-time reverse transcriptase Pcr.
results
Both gad and fad induced a relevant dose-dependent vasodilation in ZL, but not in hypoadiponectinemic ZDF rats. This effect was totally blunted by l-nitroarginine-methyl-ester indicating NO dependency. The addition of rOS inhibitors could not improve the vasodilatory effect of adiponectin. Vasodilatory response to acetylcholine was reduced in ZDF rats, which could not be enhanced by low-dose adiponectin. adiponectin receptor 1 (adipor1) was higher expressed than adiponectin receptor 2 (adipor2) with no significant differences between both animal groups, but aPPL1 was significantly decreased in ZDF rats. The eNOS expression was not significantly different between ZL and ZDF rats.
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Adiponectin Induces NO-Dependent Vasodilation seems to act as a negative regulator of adiponectin signaling in muscle cells. 19 In this process, endothelial dysfunction may be a key event, that links obesity, diabetes and cardiovascular disease. Namely, it is not only an important antecedent of atherosclerosis, but in addition, a reciprocal relationship with insulin resistance has been discussed. 20 Endothelial dysfunction is characterized by a reduced vasodilation and a shift toward a proinflammatory and prothrombotic state. Thereby, a key feature is the reduced production of nitric oxide (NO), which induces endotheliumdependent vasodilation, inhibits inflammation and exerts antiaggregant effects on platelets. A reduced activity of endothelial NO synthase (eNOS), a decreased NO bioavaibility and inhibiting effects of reactive oxygen species (ROS) are discussed as causative factors for NO deficiency. 21 In the last years, there were several indications in clinical and experimental studies, that adiponectin has vasoprotective properties and directly influences endothelial function. 22, 23 But its direct effect on resistance arteries has not yet been studied in detail.
In the present study, we tested, whether both gAd and fAd induce NO-dependent vasodilation in resistance arteries of ZDF rats and their nondiabetic littermates, the Zucker lean (ZL) rats. Further, we evaluated, whether an additional administration of the ROS inhibitors tempol and catalase enhances the effects of gAd, and investigated, whether gAd or fAd can improve vasodilatory response to acetylcholine (ACh) in endothelial dysfunction. To detect possible alterations in the adiponectin signaling pathway, we measured the mRNA expression of both adiponectin receptors, the adaptor protein APPL1 and APPL2 as well as eNOS.
Methods
Animal experiments. The study was approved by the local committee on animal research and is in accordance with the "Guide for the Care and Use of Laboratory Animals" published by the US National Institutes of Health. Six male ZDF rats (fa/fa) and six male ZL rats (fa/−) were studied from an age of 13 weeks until an age of 24 weeks. Of notice, one ZDF rat died during the experiment, so that in this group only five animals could be analyzed. The animals were individually housed on a 12-h dark/12-h light cycle. They were fed a Purina 5008 rat chow containing 23% protein, 6.5% fat, 58.5% carbohydrates, 4% fiber and 8% ash. Rats received tap water ad libitum. In week 13 and 22 systolic blood pressure and heart rate was assessed by tail cuff method using an automated cuff inflator-pulse detection system (CODA2 Multi-Channel, Computerized, EMKA Technologies, Paris, France). At the same timepoints the animals were weighed and blood glucose was measured after 6 h fasting (ACCU-CHEK Sensor, Roche, Mannheim, Germany). Animals were killed at 24 weeks of age and the serum levels of adiponectin (B-Bridge International, Mountain View, CA) and insulin (ALPCO Diagnostic, Salem, MA) were assessed via ELISA according to the manufacturers instructions. At the end of the experiment the mesenteric vasculature was dissected for the preparation of small resistance arteries. A second set of six ZDF and six ZL rats, which was treated like the first animals, was used to do additional investigations.
Preparation and study of small resistance arteries. A thirdorder branch of the mesenteric artery was isolated, cleaned from fat and connecting tissue, and mounted on a pressure myopraph (DMT, Aarhus, Denmark). First, thickness of the vessels media and the lumen diameters were measured. Then after precontraction with 10 -5 mol/l norepinephrine, endothelium-dependent and independent relaxation was assessed with ACh (10 -9 -10 -4 mol/l) and sodium nitroprusside (SNP) (10 -5 -10 -2 mol/l), respectively. To evaluate the endothelial vasodilator function of adiponectin the small arteries were exposed to cumulative doses of both gAd and fAd (0.03125-0.5 µg/ml) (AXXORA, Lörrach, Deutschland) after precontraction with 10 -5 mol/l norepinephrine. To see, if this effect is NO dependent, we also tested the action of adiponectin after preincubation with 10 -5 mol/l l-nitroarginine-methyl-ester (l-NAME), an inhibitor of the eNOS. The vessels were first incubated with l-NAME for 20 min and l-NAME was additionally administrated with the cumulative doses of adiponectin as previously. Further, we investigated, whether in the state of endothelial dysfunction the addition of gAd or fAd can improve the vasorelaxation to acetylcholine. Therefore vessels were first incubated with 0.125 µg/ml gAd or fAd for 20 min and then gAd or fAd was added in the same concentration to rising doses of acetylcholine (10 -9 -10 -4 mol/l).
In a second set of rats consisting of 24 weeks old diabetic ZDF (n = 6) and normoglycemic ZL rats (n = 6) a repetition of gAd in concentrations up to 4 µg/ml was performed. Furthermore the question, whether differences in the response to adiponectin between ZDF and ZL rats is caused by an overproduction of ROS, was addressed by a 20 min preincubation of the vessel and addition of two ROS inhibitors, tempol (10 -3 mol/l) and catalase (120 U/ml), to gAd (0.03125-1 µg/ml).
In all experiments the vasodilation of the vessels was calculated as percentage after a maximal precontraction with 10 -5 mol/l norepinephrine using the following formula: vasodilation (%) = (DX − DNE)/(DR − DNE) × 100. Thereby DX is the actual measured diameter at a given concentration of adiponectin, ACh or SNP. DNE is the diameter under precontration with norepinephrine, and DR is the resting diameter of the vessel.
Expression of adiponectin receptors, APPL1, APPL2, and eNOS.
The expression of both adiponectin receptors (AdipoR1 and AdipoR2), APPL1, APPL2, and eNOS in the small arteries was measured by using a real-time reverse transcriptase PCR. Therefore same calibre branches of the mesenteric artery were collected and cleaned from adipose and connecting tissue. Total RNA was extracted using RNeasy kit (Quiagen, Hilden, Germany) according to the manufacturers instructions. For first-strand cDNA synthesis, 1 µg total RNA was reverse transcribed with 1 U MMLV Reverse Transcriptase, 1 µg Random Primer, 1 mmol/l deoxynucleotide triphosphate mixture, 1 µl recombinant RNasin ribonuclease inhibitor and transcription
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Adiponectin Induces NO-Dependent Vasodilation buffer with 5 mmol/l MgCl 2 in a final volume of 10 µl (all from Promega, Mannheim, Germany). The reaction mixture was incubated at 37 °C for 60 min, followed by heat inactivation of the enzyme at 95 °C for 5 min. After cooling on ice for 5 min, the cDNA was stored at −20 °C. In parallel, 1 µg total RNA were processed without reverse transcription to control for contamination with genomic DNA. Real-time reverse transcriptase PCR detection of adiponectin receptors, APPL1, APPL2, and eNOS was carried out using the AbiPrism 7900 TaqMan (Applied Biosystems, Foster City, CA). Cyclophilin B and β-actin were used as housekeeping genes for normalization. Designed primers for APPL1, APPL2, and Cyclophilin B bridging at least one intron were purchased from MWG-Operon (Ebersberg, Germany). The following primers were used: APPL1_fw: 5′-AGA GAC CCT GGA GGA CAG TCC G-3′, APPL1_rev: 5′-AGG TGT GTT GCT GCA CTC AAT TCA T-3′, APPL2_ fw: 5′-GCA GGC GAT GCA GCG TGT CT-3′, APPL2_rev: 5′-TTC GTC GCC TTT GCC CAG TGC-3′. Sequence analyses were performed to verify the correct amplicons (Entelechon, Regensburg, Germany). Using the blast algorithm we confirmed that APPL1 matched to the predicted APPL1 mRNA-sequence in the rat genome. Parallelism of amplification curves of the test and control was confirmed. The TaqMan probes for AdipoR1 and AdipoR2, for eNOS, and for β-actin were purchased from Applied Biosystems (Foster City, CA).
Statistical analysis. For the biometric data of blood pressure, heart rate, blood glucose, weight, and serum levels of adiponectin the means of every measurement for the ZDF and ZL rats were calculated. Groups were compared using the Students t-test or one-way analysis of variance as appropriate. The curves created from the measurements in the small vessel myograph were compared using two-way analysis of variance for repeated measurements. All data are presented as means ± s.e.m. A P value of <0.05 was considered to be significant. Table 1 shows the biometric data of ZL and ZDF rats at an age of 13 and 22 weeks. As expected, ZDF rats demonstrated already at an age of 13 weeks significantly elevated blood glucose levels in terms of diabetes mellitus type 2, while their littermates, the ZL rats, showed normal blood glucose levels. Until an age of 22 weeks the differences in both groups persisted under a high-caloric diet. Heart rate at an age of 13 weeks was significantly higher in ZL than in ZDF rats and only tended to be higher at an age 22 weeks. No significant differences could be observed for the systolic blood pressure as well as the body weight at both time points. Serum adiponectin levels in week 24 were significantly higher in ZL than in ZDF rats (4.03 ± 0.08 vs. 2.93 ± 0.19 µg/ml; P < 0.001), insulin levels were not significantly different between both animal gropus (ZL vs. ZDF: 1.88 ± 0.19 vs. 1.47 ± 0.14; P = n.s.). Importantly, the second set of animals showed analogous biometric characteristics to the first set (data not shown).
results

Biometric data of Zl and ZdF rats
relaxation response to adiponectin
After precontraction with norepinephrine there was a clear vasodilatory dose-response relationship for gAd as well as fAd in ZL rats. The maximum vasodilation was reached at a concentration of 0.25 µg/ml for gAd (21.0%) and 0.5 µg/ ml for fAd (23.5%). Both curves were statistically not different (Figure 1 ). Higher doses up to 4 µg/ml did not further improve vasodilation to gAd (data not shown). In contrast, in ZDF rats neither gAd nor fAd resulted in a relevant 
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Adiponectin Induces NO-Dependent Vasodilation vasodilation. This was statistically significant compared with the ZL rats (P < 0.001). To evaluate, if this vasodilatory response of the small arteries of the nondiabetic ZL rats was NO dependent, we performed the same dose-response experiments for gAd and fAd after a 20 min preincubation and an additional administration of l-NAME, an inhibitor of eNOS. The initially noted effect of gAd and fAd was totally blunted by l-NAME (Figure 2) indicating, that the vasodilatory effect of adiponectin is exclusively mediated by NO. In ZDF rats, where adiponectin showed no vasodilation, preincubation and additional administration of l-NAME expectedly had no effect (data not shown). Furthermore the preincubation with the two ROS inhibitors, tempol and catalase, to gAd could not cause an improvement in the vasodilatory response in ZDF as well as ZL rats in our experimental setup (Figure 3) .
expression of adiponectin receptors, aPPl1, aPPl2, and enos
To test whether the difference in the vasorelaxation to both gAd and fAd between ZL and ZDF rats is caused by alterations in the adiponectin signaling pathway, we performed an expression analysis for both receptors (AdipoR1 and AdipoR2), APPL1, APPL2, and eNOS in the vascular tissue by real-time reverse transcriptase PCR. AdipoR1 is expressed in a greater amount compared with AdipoR2 in the small arteries of both animal models (ZL: AdipoR1 1.06 ± 0.02 vs. AdipoR2 0.62 ± 0.01; P < 0.001; ZDF: AdipoR1 1.06 ± 0.03 vs. AdipoR2 0.68 ± 0.03; P < 0.001). But between ZL and ZDF rats AdipoR1 
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Adiponectin Induces NO-Dependent Vasodilation and AdipoR2 were not significantly different expressed. In particular, we could find no downregulation of adiponectin receptors in ZDF rats. Further, we could show that APPL1 and APPL2 are expressed in ZL and ZDF rats (Figure 4) . Thereby, APPL1 is ~25% statistically significant reduced in ZDF (n = 4) compared to ZL rats (n = 6) (ZL vs. ZDF: 0.76 ± 0.06 vs. 0.57 ± 0.04; P = 0.04). APPL2 expression is slightly, but not significant, upregulated in ZDF rats (ZL vs. ZDF: 1.24 ± 0.06 vs. 1.35 ± 0.15; P = n.s.). Additionally, the expression of eNOS was not statistically significant different (ZL vs. ZDF: 0.86 ± 0.05 vs. 0.96 ± 0.08; P = n.s.).
relaxation response to acetylcholine and snP
To assess the endothelium-dependent and independent vasodilation, small arteries were stimulated with ACh and SNP after precontraction with norepinephrine ( Figure 5 ). Endotheliumdependent vasodilation was blunted in ZDF rats, indicating endothelial dysfunction in these animals. This findings are in line with other studies, which could show endothelial dysfunction in ZDF rats. [24] [25] [26] [27] Endothelium-independent vasodilation as assessed by SNP tended to be lower in ZDF rats, but the difference was not statistically significant.
relaxation response to acetylcholine and an additional administration of adiponectin
To test whether low-dose adiponectin is able to restore impaired vasorelaxation to acetylcholine in ZDF rats, we evaluated the effect of 20 min preincubation and an additional administration of 0.125 µg/ml either gAd or fAd to increasing concentrations of ACh in ZL and ZDF rats. In both animal models the additional treatment with gAd as well as fAd caused no significant improvement in the vasorelaxation of the vessels (Figures 6 and 7) . The major findings of this study were the following: (i) both gAd and fAd are capabale of inducing a direct dose-dependent vasorelaxation in resistance arteries of nondiabetic ZL rats; (ii) this vasodilatory effect is NO dependent; (iii) diabetic ZDF rats exhibit hypoadiponectinemia and endothelial dysfunction; (iv) neither gAd nor fAd induced a relevant vasodilation of the resistance arteries of ZDF rats; (v) preincubation with ROS inhibitors could not ameliorate the lack of vasodilation; (vi) additional administration of low-dose gAd or fAd could not improve ACh-induced vasorelaxation in vitro; (vii) AdipoR1 is higher expressed than AdipoR2 in the vasculature of resistance arteries but both are not downregulated in ZDF rats; (viii) APPL1 and APPL2 is expressed in small mesenteric resistance arteries with a significant decrease of APPL1 in ZDF rats; (ix) eNOS is expressed at the same levels in both animal groups. In the last years there was rising evidence, that adiponectin has also vasoprotective properties and that low levels of adiponectin are associated with endothelial dysfunction as early stage of atherosclerosis, but also with advanced cardiovascular complications. Of interest, there are also indications, that adiponectin directly influences endothelial function. Clinical experiments in healthy humans, 28,29 diabetic 30 and hypertensive 31 patients could show a correlation of plasma adiponectin levels and endothelial vasodilatory response indirectly by measuring forearm blood flow in response to hypoxemia. An association of hypoadiponectinemia with endothelial dysfunction was confirmed in adiponectin-KO mice, which displayed a reduced vasodilatory response to acetylcholine. 31 Meanwhile, in several endothelial cell culture experiments adiponectin provoked NO production. Chen et al. 32 described that fAD directly stimulates NO production in bovine aortic endothelial cells and in the same year Hattori et al. 33 demonstrated that also globular adiponectin increases NO production in vascular endothelial cells through activation of the eNOS and by increasing eNOS expression. This effect seems to be mediated by AdipoR1 and AdipoR2, which are also expressed on endothelial cells. 18 To our knowledge, the question whether adiponectin with its ability to increase endothelial NO production exhibits NO-dependent vasorelaxation in resistance arteries, the site of regulation of peripheral resistance, is not yet studied in detail. Only Cheng et al. 18 stimulated additionally to their cell culture experiments mesenteric resistance arteries with adiponectin in a wire myograph and could show a vasodilatory response.
In the present study, we could show that both gAd and fAd are able to induce a relevant vasodilation in the resistance arteries of nondiabetic ZL rats (Figure 1 ). This vasodilatory effect may directly contribute to adiponectin mediated blood pressure lowering and the association between hypoadiponectinemia and hypertension observed in experimental and epidemiological studies. 34, 35 Because the vasodilatory effect of adiponectin was totally diminished by additional administration of l-NAME (Figure 2) , the vasodilation of resistance arteries seems to be NO dependent, which is in line with the above mentioned cell culture studies, that could show that adiponectin induces NO production in endothelial cells. It is to note that plasma concentrations of adiponectin were higher than concentrations elucidating maximal vasodilation in our setting. This might indicate a constant vasodilatory action of adiponectin in control animals. Thus, the absent vasodilatory effect of adiponectin may contribute to endothelial dysfunction in ZDF rats.
Motoshima et al. 36 additionally showed that AdipoR1 mRNA is more abundant than AdipoR2 in endothelial cells. These findings were expanded by Cheng et al., 18 who showed that the adiponectin-evoked eNOS activation is mediated by both receptors. Further Ouchi et al. 31 could show that adiponectin-KO mice develop hypertension under a high-caloric diet and exhibit an impaired vasoreactivity to ACh. Therefore, an important question is whether hypoadiponectinemia and/or a downregulation of its receptors contribute to the development of endothelial dysfunction through a decrease in NO production. original contributions
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Here we detected both adiponectin receptors in resistance arteries and also confirmed that AdipoR1 is expressed at higher levels than AdipoR2, but of interest both receptors are not downregulated in diabetic ZDF rats. Additionally, the eNOS expression in ZL and ZDF animals were not different. Therefore, in our diabetic and hypoadiponectinemic setting endothelial dysfunction and the impaired vasodilatory response to adiponectin is likely to be caused by alterations in the signaling pathway between the receptors and eNOS and/ or a reduced NO bioavailability, although we have to mention that we determined the mRNA expression, but not the activity of the adiponectin receptors and eNOS.
Indeed, in the last years there was some progress in the understanding of the intracellular adiponectin signaling, but the exact mechanisms are by far not fully revealed. 37 In the endothelium the adiponectin-evoked NO production seems to be mediated via a phosphatidylinositol-3-kinase-dependent pathway involving phosphorylation of eNOS by the AMP-activated protein kinase. 32 Thereby, APPL1 is the first described adaptor protein for the adiponectin receptors 38 and seems to play an important role in the signal transmission from the receptors to the AMP-activated protein kinase as well as in the crosstalk with the insulin signaling pathway. 39 In diabetic db/db mice Cheng et al. 18 found a decreased expression of APPL1 and a reduced vasodilation of small mesenteric arteries to adiponectin. Wang et al. 19 found a isoform of APPL1, APPL2, which acts as a negative regulator of the adiponectin pathway in muscle cells. In our study, we could find a significant reduction of APPL1 expression in the studied vessels of ZDF rats (Figure 4) , which might be a possible mechanism for decreased adiponectin signaling and NO production in diabetic ZDF rats.
Further Cao et al. 40 could show for the first time that adiponectin deficiency causes a severe endothelial dysfunction. Importantly, all pathologic alterations could be completely restored by exogenous replenishment of adiponectin. The endothelial dysfunction was caused by an increased NO inactivation due to increased superoxide production and decreased NO production due to reduced eNOS phosphorylation. Thereby, an antioxidant treatment with apocynin partially improved endothelial dysfunction and adiponectin replenishment with exogenous gAd completely restored vasodilatory response to ACh. In contrast to our study, where the preincubation with the ROS inhibitors tempol and catalase could not improve the vasodilatory response to gAd (Figure 3) , the antioxidative treatment was performed in vivo and over 3 days. So, these treatments might need a longer time to take effect. The reason, why neither the preincubation with gAd nor fAd could improve the reduced vasodilatory effect of ACh in our diabetic rats (Figures 6 and 7) , may also be founded in the short incubation time, but also in the used concentration of gAd and fAd. Higher concentrations of adiponectin to completely replenish the differences in the adiponectin serum levels between ZL and ZDF rats could be more effective.
In conclusion, we demonstrated that both gAd and fAd exhibit a NO-dependent vasodilation of resistance arteries in nondiabetic ZL, but not in diabetic ZDF rats, that exhibit hypoadiponectinemia and endothelial dysfunction. In our setting an antioxidative treatment with ROS inhibitors could not restore the vasodilatory effect of adiponectin in ZDF rats and also the addition of gAd and fAd showed no improvement in endothelial dysfunction in these animals. A possible mechanism for the reduced adiponectin signaling in our diabetic animals might be the observed alterations in the APPL1 expression.
Because of the vasoprotective properties of adiponectin, hypoadiponectinemia is thought to be a major link between diabetes mellitus and its cardiovascular comorbidities. Thereby, endothelial dysfunction as antecedent of atherosclerosis plays a crucial role. In the present study, we could show that adiponectin is able to induce a NO-dependent vasodilation of resistance arteries in nondiabetic ZL rats but not in diabetic ZDF rats. In diabetes mellitus reduced serum adiponectin levels and the observed reduced response to adiponectin, which is probably caused by alterations downstream of the two adiponectin receptors, like APPL1 downregulation, might at least in part be responsible for the development of endothelial dysfunction. Therefore further investigations to elucidate the exact intracellular signaling mechanisms of adiponectin are needed to address this topic.
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